Hígado graso no alcohólico en niños con obesidad

1. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118: 1388–93 https://doi.org/10.1542/peds.2006-1212.

2. Zhang W, Wei L. Prevalence of nonalcoholic fatty liver disease in Asia. Chin J Hepatol. 2013;21:801–4.

3. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015;10:e0140908 https:// doi.org/10.1371/journal.pone.0140908.

4. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–23 https://doi.org/10.1126/ science.1204265.

5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31 https://doi.org/10.1056/NEJMra011775.

6. Roberts EA. Nonalcoholic steatohepatitis in children. Curr Gastroenterol Rep. 2003;5:253–9 https://doi.org/10.1007/s11894-003-0028-4.

7. Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics. 2005;115:e561–5 https://doi.org/10.1542/peds.2004-1832.

8. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis. 2004;8:549–58, viii-ix https://doi.org/10.1016/j.cld.2 004.04.010.

9. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538–44 https:// doi.org/10.1136/gut.2008.171280.

10. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol. 2002; 97:2460–2 https://doi.org/10.1111/j.1572-0241.2002.06003.x.

11. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277–83 https://doi.org/10.1161/CIRCULATIONA HA.107.739920.

12. Schwimmer JB, Zepeda A, Newton KP, Xanthakos SA, Behling C, Hallinan EK, et al. Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS One. 2014;9:e112569 https://doi.org/1 0.1371/journal.pone.0112569.

13. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21 https://doi.org/10.1053/j.ga stro.2005.04.014.

14. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–54 https://doi.org/10.1002/hep.27368.

15. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGH AN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64:319–34 https://doi.org/10.1097/MPG. 0000000000001482.

16. Schwimmer JB, Newton KP, Awai HI, Choi LJ, Garcia MA, Ellis LL, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:1267–77 https://doi.org/10.1111/apt.12518.

17. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the west. Nat Rev Gastroenterol Hepatol. 2013;10:307–18 https://doi. org/10.1038/nrgastro.2013.34.

18. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73 https://doi.org/10.1002/hep.21327.

19. Mullen MC, Shield J. Pocket guide to pediatric weight management. 2nd ed; 2018.

20. McCarthy HD, Jarrett KV, Crawley HF. The development of waist circumference percentiles in British children aged 5.0–16.9 y. Eur J Clin Nutr. 2001;55:902–7 https://doi.org/10.1038/sj.ejcn.1601240.

21. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–50 https://doi.org/10.1053/gast.2002.35354.

22. Dhuper S, Cohen HW, Daniel J, Gumidyala P, Agarwalla V, St Victor R, et al. Utility of the modified ATP III defined metabolic syndrome and severe obesity as predictors of insulin resistance in overweight children and adolescents: a cross-sectional study. Cardiovasc Diabetol. 2007;6:4 https:// doi.org/10.1186/1475-2840-6-4.

23. Song P, Li X, Gasevic D, Flores AB, Yu Z. BMI, waist circumference reference values for Chinese school-aged children and adolescents. Int J Environ Res Public Health. 2016;13 https://doi.org/10.3390/ijerph13060589.

24. Subspecialty Group of Endocrinologic H, Metabolic Diseases, The Society of Pediatrics Chinese Medical Association, Subspecialty Group of Cardiology TSoPCMA, Subspecialty Groups of Child Health Care TSoPCMA. The definition of metabolic syndrome and prophylaxis and treatment proposal in Chinese children and adolescents. Chin J Pediatr. 2012;50:420–2.